Human CD40/TNFRSF5 Antibody Summary
Glu21-Arg193
Accession # P25942
Applications
Measured by its ability to neutralize CD40 Ligand/TNFSF5-induced proliferation in human B cell enriched peripheral blood mononuclear cells (PBMC). At 5 µg/mL, this anti-hCD40 antibody will neutralize approximately 80% of 10 µg/mL Recombinant Human CD40 Ligand/TNFSF5 -induced proliferation of human B-cell enriched PBMCs.
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Scientific Data
Cell Proliferation Induced by CD40 Ligand/TNFSF5 and Neutralization by Human CD40/TNFRSF5 Antibody. In the presence of Recombinant Human IL-4 (Catalog # 204-IL), Recombinant Human CD40 Ligand/TNFSF5 (Catalog # 6245-CL) stimulates proliferation in human B cell enriched peripheral blood mononuclear cells (PBMC) in a dose-dependent manner (orange line). Proliferation elicited by Recombinant Human CD40 Ligand/TNFSF5 (10 µg/mL) is neutralized (green line) by increasing concentrations of Human CD40/TNFRSF5 Monoclonal Antibody (Catalog # MAB6322). At 5 µg/mL, this anti-hCD40 antibody will neutralize approximately 80% of Recombinant Human CD40 Ligand/TNFSF5 -induced proliferation in the presence of Recombinant Human IL-4 (20 ng/mL).
Detection of CD40/TNFRSF5 Mouse by Western Blot. Western blot shows lysates of human spleen tissue. PVDF membrane was probed with 2 µg/mL of Mouse Anti-Human CD40/TNFRSF5 Monoclonal Antibody (Catalog # MAB6322) followed by HRP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # HAF007). A specific band was detected for CD40/TNFRSF5 at approximately 40 kDa (as indicated). This experiment was conducted under non-reducing conditions and using Immunoblot Buffer Group 1.
Reconstitution Calculator
Preparation and Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: CD40/TNFRSF5
CD40 is a type I transmembrane glycoprotein belonging to the TNF receptor superfamily. Mature human CD40 consists of a 172 amino acid (aa) extracellular domain, a 22 aa transmembrane region and a 62 aa cytoplasmic domain (1). Human and mouse CD40 share 62% aa identity. CD40 is expressed in B cells, follicular dendritic cells, dendritic cells, activated monocytes, macrophages, endothelial cells, vascular smooth muscle cells, and several tumor cell lines (2). The extracellular domain has the cysteine-rich repeat regions, which are characteristic for many of the receptors of the TNF superfamily. Interaction of CD40 with its ligand, CD40L, leads to aggregation of CD40 molecules, which in turn interact with cytoplasmic components to initiate signaling pathways. Early studies on the CD40-CD40L system revealed its role in humoral immunity. Interaction between CD40L on T cells and CD40 on B cells stimulated B cell proliferation and provided the signal for immunoglobulin isotype switching (3). Mutations in the CD40L gene, which resulted in a CD40L molecule unable to interact with CD40, are responsible for the hyper-IgM syndrome (4). Cross-linking of CD40 with antibodies or by CD40 binding to CD40L produces cell type-specific responses which include costimulation and induction of proliferation, induction of cytokine production, rescue from apoptosis, and upregulation of adhesion molecules (5). Some of the early events of intracellular signaling by the CD40-CD40L system include the association of the CD40 with TRAFs and the activation of various kinases (6-8).
- Torres, R.M. and E.A. Clark (1992) J. Immunol. 148:620.
- Schonbeck, U. et al. (1997) J. Biol. Chem. 272:19569.
- Armitage, R.J. et al. (1993) J. Immunol. 150:3671.
- Callard, R.E. et al. (1993) Immunol. Today 14:559.
- Stout, R.D. and J. Suttles (1996) Immunol. Today 17:487.
- Pullen, S.S. et al. (1999) Biochemistry 38:10168.
- Faris, M. et al. (1994) J. Exp. Med. 179:1923.
- Hanissian, S.H. and R.S Geha (1997) Immunity 6:379.
Product Datasheets
Citations for Human CD40/TNFRSF5 Antibody
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
9
Citations: Showing 1 - 9
Filter your results:
Filter by:
-
Ex vivo-expanded human CD19+TIM-1+ regulatory B cells suppress immune responses in vivo and are dependent upon the TIM-1/STAT3 axis
Authors: S Shankar, J Stolp, SC Juvet, J Beckett, PS Macklin, F Issa, J Hester, KJ Wood
Nature Communications, 2022-06-03;13(1):3121.
Species: Human
Sample Types: Whole Cells
Applications: Neutralization -
Structural Diversity and Anticancer Activity of Marine-Derived Elastase Inhibitors: Key Features and Mechanisms Mediating the Antimetastatic Effects in Invasive Breast Cancer
Authors: FH Al-Awadhi, VJ Paul, H Luesch
Chembiochem, 2018-03-23;0(0):.
Species: Human
Sample Types: Cell Lysates
Applications: Western Blot -
Up-Regulated Expression of Matrix Metalloproteinases in Endothelial Cells Mediates Platelet Microvesicle-Induced Angiogenesis
Authors: C Sun, SB Feng, ZW Cao, JJ Bei, Q Chen, WB Zhao, XJ Xu, Z Zhou, ZP Yu, HY Hu
Cell. Physiol. Biochem., 2017-04-27;41(6):2319-2332.
Species: Human
Sample Types: Whole Cells
Applications: Neutralization -
Circulating CXCR5(+)CXCR3(+)PD-1(lo) Tfh-like cells in HIV-1 controllers with neutralizing antibody breadth
Authors: E Martin-Gay, J Cronin, T Hickman, Z Ouyang, M Lindqvist, KE Kolb, J Schulze Zu, R Cubas, F Porichis, AK Shalek, J van Lunzen, EK Haddad, BD Walker, DE Kaufmann, M Lichterfel, XG Yu
JCI Insight, 2017-01-26;2(2):e89574.
Species: Human
Sample Types: Whole Cells
Applications: Neutralization -
A soluble form of IL-27Ralpha is a natural IL-27 antagonist.
Authors: Dietrich C, Candon S, Ruemmele F, Devergne O
J Immunol, 2014-04-25;192(11):5382-9.
Species: Human
Sample Types: Whole Cells
Applications: Neutralization -
ICOS-LICOS interaction is critically involved in TGN1412-mediated T-cell activation.
Blood, 2012-05-10;119(26):6268-77.
Species: Human
Sample Types: Whole Cells
Applications: Neutralization -
Circulating myeloid dendritic cells of advanced cancer patients result in reduced activation and a biased cytokine profile in invariant NKT cells.
Authors: van der Vliet HJ, Wang R, Yue SC, Koon HB, Balk SP, Exley MA
J. Immunol., 2008-06-01;180(11):7287-93.
Species: Human
Sample Types: Whole Cells
Applications: Neutralization -
IL-21 and BAFF/BLyS synergize in stimulating plasma cell differentiation from a unique population of human splenic memory B cells.
Authors: Ettinger R, Sims GP, Robbins R, Withers D, Fischer RT, Grammer AC, Kuchen S, Lipsky PE
J. Immunol., 2007-03-01;178(5):2872-82.
Species: Human
Sample Types: Whole Cells
Applications: Neutralization -
Soluble factors produced by activated CD4+ T cells modulate EBV latency
Authors: Nagy N, Adori M, Rasul A et al.
Proc Natl Acad Sci U S A
FAQs
No product specific FAQs exist for this product, however you may
View all Antibody FAQsReviews for Human CD40/TNFRSF5 Antibody
There are currently no reviews for this product. Be the first to review Human CD40/TNFRSF5 Antibody and earn rewards!
Have you used Human CD40/TNFRSF5 Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image